Navigation Links
K-V Pharmaceutical Names Thomas McHugh Chief Financial Officer
Date:7/15/2010

ufactures, as well as the related material adverse effect on its revenue, assets and liquidity and capital resources, as more fully described in Part I, Item 2 – "Management's Discussion and Analysis of Financial Condition and Results of Operations – Background – Discontinuation of Manufacturing and Distribution; Product Recalls; and the FDA Consent Decree" in the Form 10-Q;
  • the possibility of further reducing the Company's operations, including further reductions of its employee base and significantly curtailing some or all of its efforts to meet the consent decree's requirements and return its approved products to market in order to maintain and attempt to increase its limited cash and financial resources, and related costs and accounting charges from taking such actions;
  • the plea agreement between the Company and the U.S. Department of Justice and the Company's obligations therewith, as well as the related material adverse effect, if any, on its revenue, assets and liquidity and capital resources, as more fully described in Note 20 – "Subsequent Events" of the Notes to the Consolidated Financial Statements in the Form 10-Q;
  • changes in the current and future business environment, including interest rates and capital and consumer spending;
  • the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized;
  • the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals, including with respect to Gestiva™, as well as the number of preterm births for which Gestiva™ may be prescribed, its safety profile and side effects profile;
  • acceptance of and demand for the Company's new pharmaceutical products or current products upon their return to the marketplace;
  • the introduction and impact of competitive products and pricing, including as a result of so-called authorized generic drugs;
  • new product development
    '/>"/>

  • SOURCE K-V Pharmaceutical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
    2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
    9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/4/2015)... CITY, Kan. , March 4, 2015   ... a pet therapeutics company focused on the licensing, development ... today announced that it will present at the ... 10-12, 2015, at the Loews Miami Beach Hotel in ... Steven St. Peter , M.D., President and Chief ...
    (Date:3/4/2015)... March 4, 2015  Results of the recent study, ... Using MarginProbe for Intra-Operative Positive Margin Detection , were ... the 32 nd Annual Miami Breast Cancer Conference ... Moshe Papa , MD, FACS, Professor of Surgery ... University, reports an analysis of MarginProbe,s efficiency and accuracy ...
    (Date:3/4/2015)... 2015 Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in ... cancer, today announced that James A. Joyce , ... overview at the 27th Annual ROTH Conference on March ... Laguna Niguel, California . To learn more about ... A live webcast of the presentation will be ...
    Breaking Medicine Technology:Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2Aethlon Medical to Present at the 27th Annual ROTH Conference 2
    ... April 22 Genoptix, Inc. (Nasdaq: GXDX ), a specialized ... for the first quarter 2010 after closing of the NASDAQ Global Select Market ... , , ... , Ph.D., and other members of senior management will take place on the ...
    ... REDWOOD CITY, Calif. , April 22 Codexis, Inc. announced today ... stock, at $13.00 per share. All shares are being sold by ... an additional 900,000 shares at the initial public offering price to cover overallotments, ... the symbol "CDXS." , , , ...
    Cached Medicine Technology:Genoptix, Inc. to Announce First Quarter 2010 Financial Results 2Genoptix, Inc. to Announce First Quarter 2010 Financial Results 3Codexis, Inc. Announces Pricing of Initial Public Offering 2
    (Date:3/4/2015)... Jeannie Mai, TV personality, fashion maven, and co-host ... of the print publication. Mai embraces the overall theme of ... for clothes and personal care products. In an exclusive interview, ... to an organic diet. She mentions, “Having an organic lifestyle ... but also now as I’m a full time student at ...
    (Date:3/4/2015)... Today Visiopharm announces that Patrik Dahlén, previously the ... Visiopharm Board of Directors as Chairman. Mr. ... positioned to become the fastest growing software company, specializing ... , "Over the last several years, Visiopharm ... ONCOtopix™ Dx, a complete quantitative digital pathology solution for ...
    (Date:3/4/2015)... March 04, 2015 Problem Gambling Awareness ... to join individuals and organizations across the nation in ... public, health care professionals, policymakers, and others about problem ... on Compulsive Gambling (FCCG) and FCCG partner organizations are ... screen patients for a gambling problem, to make treatment ...
    (Date:3/4/2015)... (PRWEB) March 04, 2015 A new ... showing promise in terms of extending life. Studies ... that this new dieting routine can help extend life ... production clearly has long term benefits, many suffering from ... a quicker substitute is necessary. As an alternative to ...
    (Date:3/4/2015)... 04, 2015 Dietary supplement company ... world’s first biocompatible copper chelate, at Natural Products Expo ... the chance to gain insight into their wellness through ... Cunermuspir complex can support their individual nutritional needs, all ... is the core ingredient of the MitoSynergy product line, ...
    Breaking Medicine News(10 mins):Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 2Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 3Health News:Problem Gambling - A Public Health Issue; March Is Problem Gambling Awareness Month 2Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 2Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 3Health News:MitoSynergy Invites Expo West Attendees to Sit Back, Relax and Take Time for Their Health 2
    ... scientists have said that degradation of the eco systems// of ... and may cause greater harm in next 50 years. ... a major outbreak and new diseases are emerging because of ... being used in unsustainable way. ,The report emphasizes that ...
    ... drug raloxifene, used for treating osteoporosis is also able to ... are in their postmenopausal age. ,The study observed women ... mg of raloxifene daily for bone fractures due to osteoporosis ... After three years, all women were tested for cognitive impairments ...
    ... completed the second phase of testing of the vaccine ... cervical cancers and 90% of genital warts. ,277 ... 36 months and regularly had gynecological examination, cervicovaginal sampling ... antibodies to HPV. , ,The results showed the ...
    ... onions may be the key to avoid the risk of ... in onions, a peptide called GPCS that seems to prevent ... cells of newborn mice that were treated with parathyroid hormone ... exposed to the peptide GPCS. The treatment with the peptide ...
    ... In a study trying to find out the relationship between ... 585 confirmed cases of pancreatic cancer and 4779 healthy people ... pancreas is pancreatic cancer and it spreads through the lymphatic ... smoking etc had been known to increase the risk of ...
    ... the risk of diabetes. Obese people may be a t ... A study by UT Southwestern Medical Center of US suggests ... have a genetic component. ,The study had evaluated ... type II in people. The study was conducted on 679 ...
    Cached Medicine News:
    ... Stryker's cystoscope line combines ... intuitive and durable hardware. ... incorporate a robust, ergonomic ... connection found on Stryker ...
    ... The new EndoEYE Flexible Video Cystoscope from ... surgical technology. By marrying proprietary video chip ... Olympus is now providing a flexible video ... that of a rigid rod lens system. ...
    The Olympus continuous flow cystoscope was especially designed for laser treatment of the prostate and for collagen injection....
    ... is an advanced transurethral microwave thermotherapy ... benign prostate hyperplasia (BPH). TherMatrx is ... thermotherapy treatment in the United States. ... does not require cutting, heavy sedation ...
    Medicine Products: